What is Brainstorm Cell Therapeutics I's earnings per share (EPS)?

Brainstorm Cell Therapeutics I (BCLI) reported diluted earnings per share of $-1.11 for fiscal year 2025. This represents a 51.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Brainstorm Cell Therapeutics I Financials

BCLI

Source SEC Filings (10-K/10-Q) Updated May 15, 2026 Currency USD FYE December

This page shows Brainstorm Cell Therapeutics I (BCLI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BCLI FY2025 2026-05-15

Funding dependence still defines BrainStorm, as expense cuts reduced burn faster than they rebuilt liquidity.

Operating cash burn was cut by roughly two-thirds between FY2021 and FY2024, yet cash on hand nearly vanished over the same stretch. That combination, alongside a current ratio falling from 3.7x to 0.04x, shows expense reduction bought time but did not create operations that refill the balance sheet.

By FY2025, total liabilities were about eleven times total assets, leaving very little balance-sheet cushion if obligations come due before new funding arrives. With only $29K of cash and negative equity, the asset base now looks more like a thin bridge than a reserve.

Financing inflows in FY2023 and FY2024 were large enough to offset much of the annual cash burn, so survival depended on fresh capital rather than internally generated funds. Because no long-term debt is reported, that bridge appears to have come mainly from outside investors while working-capital pressure kept tightening.

Financial Health Signals

Financial Profile 15/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Brainstorm Cell Therapeutics I's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Brainstorm Cell Therapeutics I carries a low D/E ratio of -1.10, meaning only $-1.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 92/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Brainstorm Cell Therapeutics I's current ratio of 0.03 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-1.11

YoY+51.9%

Brainstorm Cell Therapeutics I earned $-1.11 per diluted share (EPS) in fiscal year 2025. This represents an increase of 51.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$29K

YoY-84.5%

5Y CAGR-76.2%

10Y CAGR-23.6%

Brainstorm Cell Therapeutics I held $29K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

11M

YoY+79.7%

Brainstorm Cell Therapeutics I had 11M shares outstanding in fiscal year 2025. This represents an increase of 79.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$4.2M

YoY-10.2%

5Y CAGR-28.5%

10Y CAGR-1.7%

Brainstorm Cell Therapeutics I invested $4.2M in research and development in fiscal year 2025. This represents a decrease of 10.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

BCLI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.2M-10.2%	$4.7M-56.7%	$10.7M-23.0%	$14.0M-8.4%	$15.2M-31.8%	$22.3M
SG&A Expenses	N/A	$7.0M-34.1%	$10.7M-1.6%	$10.9M+16.8%	$9.3M-0.5%	$9.4M
Operating Income	N/A	N/A	N/A	-$24.8M-1.2%	-$24.5M+22.6%	-$31.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	-$17.2M+29.2%	-$24.3M+0.7%	-$24.5M+23.1%	-$31.8M
EPS (Diluted)	$-1.11+51.9%	$-2.31+61.5%	$-6.00	$-0.66+2.9%	$-0.68+36.4%	$-1.07

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$762K	N/A	$899K-19.7%	$1.1M-14.1%	$1.3M	N/A	$1.0M+13.3%	$922K
SG&A Expenses	$1.3M	N/A	$1.1M-21.0%	$1.5M-18.6%	$1.8M	N/A	$2.0M-2.8%	$2.1M
Operating Income	-$2.0M	N/A	-$2.0M+20.4%	-$2.6M+16.7%	-$3.1M	N/A	-$3.0M-2.2%	-$3.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.1M	N/A	-$2.1M+27.5%	-$2.9M-1.4%	-$2.9M	N/A	-$2.7M-6.6%	-$2.5M
EPS (Diluted)	$-0.19	N/A	$-0.19+44.1%	$-0.34+24.4%	$-0.45	N/A	$-0.51	$-0.60

BCLI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.0M-44.2%	$1.8M-56.5%	$4.2M-50.2%	$8.5M-71.1%	$29.3M-42.9%	$51.3M
Current Assets	$307K-20.3%	$385K-79.7%	$1.9M-38.9%	$3.1M-86.7%	$23.3M-46.2%	$43.2M
Cash & Equivalents	$29K-84.5%	$187K-85.6%	$1.3M+68.4%	$772K-95.9%	$18.9M-50.2%	$37.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.0M+14.7%	$9.6M+5.8%	$9.1M-20.9%	$11.5M+15.4%	$9.9M-37.1%	$15.8M
Current Liabilities	$11.0M+22.6%	$9.0M+15.1%	$7.8M-11.4%	$8.8M+39.3%	$6.3M-43.8%	$11.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$10.0M-28.6%	-$7.8M-59.8%	-$4.9M-61.1%	-$3.0M-115.6%	$19.3M-45.5%	$35.5M
Retained Earnings	-$236.9M-4.5%	-$226.6M-5.4%	-$215.0M-8.7%	-$197.8M-14.0%	-$173.5M-16.4%	-$149.1M

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$755K-26.1%	$1.0M-25.9%	$1.4M-46.2%	$2.6M-28.1%	$3.6M+94.9%	$1.8M-9.5%	$2.0M-64.4%	$5.7M
Current Assets	$184K-40.1%	$307K-39.6%	$508K-66.5%	$1.5M-35.0%	$2.3M+505.7%	$385K+5.8%	$364K-90.5%	$3.8M
Cash & Equivalents	$15K-48.3%	$29K+480.0%	$5K-99.4%	$824K-49.9%	$1.6M+779.1%	$187K+11.3%	$168K-95.2%	$3.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.8M+6.9%	$11.0M+21.3%	$9.1M+5.2%	$8.6M-21.8%	$11.0M+14.9%	$9.6M+18.7%	$8.1M-12.2%	$9.2M
Current Liabilities	$11.8M+6.9%	$11.0M+22.0%	$9.0M+5.8%	$8.5M-21.8%	$10.9M+21.4%	$9.0M+26.8%	$7.1M-7.9%	$7.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$11.0M-10.3%	-$10.0M-29.8%	-$7.7M-27.0%	-$6.1M+18.8%	-$7.5M+4.0%	-$7.8M-28.2%	-$6.1M-71.7%	-$3.5M
Retained Earnings	-$239.1M-0.9%	-$236.9M-1.0%	-$234.5M	N/A	-$229.5M-1.3%	-$226.6M-1.3%	-$223.7M-1.2%	-$221.0M

BCLI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	N/A	-$9.1M+55.6%	-$20.5M-5.9%	-$19.3M+26.4%	-$26.3M+25.4%	-$35.2M
Capital Expenditures	N/A	N/A	$18K-37.9%	$29K-91.2%	$330K-12.7%	$378K
Free Cash Flow	N/A	N/A	-$20.5M-5.8%	-$19.3M+27.2%	-$26.6M+25.2%	-$35.6M
Investing Cash Flow	N/A	$12K-99.5%	$2.2M+119.7%	$998K+209.0%	$323K+107.3%	-$4.5M
Financing Cash Flow	N/A	$8.0M-58.0%	$19.0M+7873.9%	$238K-96.6%	$7.0M-90.9%	$76.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$116K

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$1.3M-78.4%	-$740K+32.8%	-$1.1M+68.5%	-$3.5M-114.7%	-$1.6M-55.6%	-$1.0M+68.2%	-$3.3M-96.0%	-$1.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$1.3M+60.3%	$780K+149.2%	$313K-88.4%	$2.7M-12.5%	$3.1M+191.7%	$1.1M	$0-100.0%	$4.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BCLI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	-126.4%-36.7pp	-89.7%
Return on Assets	N/A	N/A	-408.6%-121.3pp	-287.3%-203.7pp	-83.5%-21.5pp	-62.1%
Current Ratio	0.03-0.0	0.04-0.2	0.24-0.1	0.35-3.3	3.69-0.2	3.85
Debt-to-Equity	-1.10+0.1	-1.24+0.6	-1.87+1.9	-3.80-4.3	0.51+0.1	0.45
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-281.7%	N/A	-152.6%-39.5pp	-113.1%-32.9pp	-80.2%	N/A	-133.7%-89.0pp	-44.7%
Current Ratio	0.02-0.0	0.03-0.0	0.06-0.1	0.18-0.0	0.21+0.2	0.040.0	0.05-0.4	0.50
Debt-to-Equity	-1.07+0.0	-1.10+0.1	-1.18+0.2	-1.42+0.1	-1.48-0.2	-1.24+0.1	-1.33+1.3	-2.61
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$10.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Alzamend Neuro Inc ALZN

$4.6M

TNF Pharmaceuticals TNFA

$9.6M

Adial Pharmaceuticals Inc ADIL

$5.0M

Hcw Biologics Inc. HCWB

$16.4M

Aim Immunotech AIM

$3.9M

Frequently Asked Questions

What are Brainstorm Cell Therapeutics I's total assets?

Brainstorm Cell Therapeutics I (BCLI) had $1.0M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Brainstorm Cell Therapeutics I spend on research and development?

Brainstorm Cell Therapeutics I (BCLI) invested $4.2M in research and development during fiscal year 2025.

How many shares does Brainstorm Cell Therapeutics I have outstanding?

Brainstorm Cell Therapeutics I (BCLI) had 11M shares outstanding as of fiscal year 2025.

What is Brainstorm Cell Therapeutics I's current ratio?

Brainstorm Cell Therapeutics I (BCLI) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Brainstorm Cell Therapeutics I's debt-to-equity ratio?

Brainstorm Cell Therapeutics I (BCLI) had a debt-to-equity ratio of -1.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Brainstorm Cell Therapeutics I's debt-to-equity ratio negative or unusual?

Brainstorm Cell Therapeutics I (BCLI) has negative shareholder equity of -$10.0M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Brainstorm Cell Therapeutics I?

Brainstorm Cell Therapeutics I (BCLI) scores 15 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.